Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (106)	11/5/2002 11:44:26 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SGMO Was up 40.63% on volume of 133,400 (about 3x its daily average) It announced yesterday the publication in Nature Medicine of data that demonstrates the utility of zinc finger DNA binding protein transcription factors (ZFP TFs) as a new class of human therapeutics. The experiments in the article, titled "Induction of angiogenesis in a mouse model using engineered transcription factors," were conducted by Frank Giordano, MD, at Yale. biz.yahoo.com Reuters had released the information on Sunday. biz.yahoo.com The stock closed strong today. (At its intra-day H of $3.15) siliconinvestor.com And seems ready to test the September 20 H at $3.20 siliconinvestor.com The P,S,M & L on SGMO: 3.15, 2.44, 2.10 & 2.29 (The L is still above the M) Bernard